Abstract THU0184 – Figure 1. Effect of Anti-drug Antibody on ACR20 Response Rates

Conclusions: In a pooled analysis, the development of ADABs to TNFi is associated with reduced clinical efficacy and increased incidence of ISR/IRR in patients with RA.

REFERENCES:

- [1] Emery, et al. *Ann Rheum Dis* 2017 Jan;76(1):51–57.
- [2] Choe, et al. *Ann Rheum Dis* 2017 Jan;76(1):58–64.
- [3] Weinblatt, et al. *Arthritis Rheumatol* 2018 Jan;70(1):40–48.

Disclosure of Interest: P. Emery Consultant for: Pfizer, MSD, AbbVie, Bristol-Myers Squibb, UCB, Roche, Novartis, Samsung, Sandoz and Lilly, M. Weinblatt Grant/research support from: Amgen, Bristol-Myers Squibb, Crescendo Bioscience, Sanofi, Consultant for: AbbVie, Amgen, Novartis, Roche, GlaxoSmithKline, Merck, Samsung, Crescendo Bioscience, and AstraZeneca, and Bristol-Myers Squibb, Lilly, Pfizer, and UCB, J. Smolen Grant/research support from: AbbVie, Janssen, MSD, Pfizer, Roche and UCB, Consultant for: AbbVie, Amgen, AstraZeneca, Astra-Pharma, Celgene, GSK, Janssen, Lilly, Medimmune, MSD, Novartis-Sandoz, Novo Nordisk, Pfizer, Roche, Samsung Bioepis, Sanofi and UCB, E. Keystone Consultant for: Abbott, AstraZeneca, Bristol-Myers Squibb, Crescendo Bioscience, F. Hoffmann-La Roche, Genentech, Janssen, Lilly, Merck, Pfizer, UCB, Samsung Bioepis, M. Genovese Consultant for: Samsung, Merck, Abbvie, Amgen, BI, J. Vencovsky Consultant for: Samsung Bioepis, Biogen, J. Kay Consultant for: Alexion; Amgen; AbbVie; AstraZeneca; Boehringer Ingelheim; BMS; Crescendo Bioscience; Eli Lilly; Epirus; Genentech; GlaxoSmithKline; Hospira; Janssen; MSD; Novartis; Pfizer; Samsung Bioepis; Sandoz; Roche; UCB, E. Hong Employee of: Samsung Bioepis, Y. Baek Employee of: Samsung Bioepis, J. Ghil Employee of: Samsung Bioepis

DOI: 10.1136/annrheumdis-2018-eular.4362

THU0185

THE VALUE OF ADALIMUMAB TROUGH LEVELS AND CLINICAL ASSESSMENTS IN PREDICTING CLINICAL RESPONSE IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO METHOTREXATE

J. Smolen¹, N. Mostafa², X. Huang², P. Noertersheuser³, B. Kluender³, K. Chen², J. Kalabic³, I. Sainsbury², R. Oerlemans⁴, S. Florentinus⁴, G. Burmester⁵. ¹Medical University of Vienna, Vienna, Austria; ²AbbVie Inc., North Chicago, USA; ³AbbVie GmbH and Co. KG, Ludwigshafen, Germany; ⁴AbbVie B.V., Hoofddorp, Netherlands; ⁵Charité – Universitätsmedizin, Berlin, Germany

Background: Low trough levels of the tumour necrosis factor inhibitor, adalimumab (ADL), and anti-ADL antibodies (AAA) were reported to be correlated with lack of response at later time points in patients (pts) with rheumatoid arthritis (RA).¹

Objectives: To assess the ability of ADL trough levels and clinical assessments at Week 12 to predict clinical remission (REM) after 24 weeks (wks) of treatment with ADL+methotrexate (MTX) in established RA pts.

Methods: Data from MTX inadequate responders (MTX-IR) pts with established RA with available measurement of ADL trough levels and clinical assessments at Wks 12 and 24 from several clinical trials were pooled: for pts who received ADL+MTX combination therapy from DE009, DE019, M10–261 and M13–390; for pts who received ADL monotherapy from DE011, M10–261 and M13–390. Efficacy endpoints at Wk 24 were DAS28-CRP<2.6 and DAS28-CRP low disease activity (LDA,<3.2), remission (REM) and LDA by simplified disease activity index (SDAI,<3.3 and<11 respectively); REM and LDA by clinical disease activity index (CDAI,<2.8 and<10 respectively). Each of the pooled datasets was randomly and equally split into training and testing sets. Predictive modelling was performed on

the training set, and the best-performing model was selected and validated in the testing set. The performance of the final model was reported based on the testing set.

Results: Based on the cutoffs selected by the predictive model, ADL concentrations at Wk 12 were only slightly predictive for Wk 24 clinical assessment in the ADL monotherapy group, but not in the ADL+MTX group (table 1). However, based on achievement of the specified CDAI, SDAI or DAS28-CRP score at Wk 12 (selected by the model), pts were correctly predicted to reach Wk 24 REM or LDA with an accuracy of 80%–90% and area under the receiver operating characteristic curve (AUC) of 75%–90% (table 2). As an example, pts on ADL monotherapy with DAS28 <3.3 at Wk 12 had 60% and 70% chance of reaching Wk 24 DAS28-CRP<2.6 and LDA respectively, whereas pts with DAS28 ≥3.3 had 0% and 7% chance of achieving Wk 24 DAS28-CRP<2.6 and LDA, respectively (table 1). Pts on ADL+MTX with Wk 12 SDAI<12.5 had a 25% and 77% chance of achieving SDAI REM and LDA at Wk 24, respectively.

Abstract THU0185 – Table 1

Ability of Week 12 Drug Concentration to Predict Disease Control at Week 24 in Patients Treated with ADL +/- MTX												
Week 24 Endpoints	Week 12 conc (µg/ml)	High conc resp rate (n)	Low conc resp rate (n)	Sensitivity	Specificity	PPV	NPV	AUC				
ADL Monotherapy												
DAS28 <2.6	>7.62	0.36 (11)	0.05 (42)	0.67	0.85	0.36	0.95	0.76				
CDAI REM	>7.62	0.27 (11)	0.05 (42)	0.60	0.83	0.27	0.95	0.72				
SDAI REM	>7.62	0.27 (11)	0.05 (42)	0.60	0.83	0.27	0.95	0.72				
DAS28 LDA	>6.53	0.42 (12)	0.122 (41)	0.50	0.84	0.42	0.88	0.77				
CDAI LDA	>7.27	0.46 (11)	0.143 (42)	0.46	0.86	0.46	0.86	0.77				
SDAI LDA	>6.806	0.42 (12)	0.171 (41)	0.42	0.83	0.42	0.83	0.74				
ADL + MTX Combination Therapy												
DAS28 <2.6	>9.03	0.24 (46)	0.24 (86)	0.34	0.65	0.24	0.76	0.50				
CDAI REM	>7.43	0.10 (68)	0.11 (64)	0.5	0.48	0.10	0.89	0.49				
SDAI REM	>7.02	0.11 (70)	0.10 (62)	0.57	0.48	0.11	0.90	0.52				
DAS28 LDA	>8.87	0.41 (49)	0.42 (83)	0.36	0.62	0.41	0.58	0.52				
CDAI LDA	>4.50	0.42 (100)	0.44 (32)	0.75	0.24	0.42	0.56	0.46				
SDAI LDA	>9.00	0.46 (46)	0.47 (66)	0.34	0.65	0.46	0.54	0.51				
Ability of Selected Week 12 Clinical Scores to Predict Disease Control at Week 24 in Patients Treated with ADL +/- MTX												
Week 24 Endpoints	Week 12 Cutoff	n	pts meeting cut-off	pts not meeting cut-off	n	resp. rate	Sensitivity	Specificity	PPV	NPV	Accuracy	AUC
ADL Monotherapy												
DAS28 <2.6	DAS28 <3.3	10	0.60	43	0.0	1.00	0.92	0.60	1.00	0.93	0.96	
CDAI REM	CDAI <9.6	8	0.63	45	0.0	1.00	0.94	0.63	1.00	0.94	0.97	
SDAI REM	SDAI <11.5	10	0.50	43	0.0	1.00	0.90	0.50	1.00	0.91	0.95	
DAS28 LDA	DAS28 <3.3	10	0.70	43	0.07	0.70	0.93	0.70	0.93	0.89	0.82	
CDAI LDA	CDAI <11.4	10	0.70	43	0.09	0.64	0.93	0.70	0.91	0.87	0.78	
SDAI LDA	SDAI <12.7	10	0.80	43	0.09	0.67	0.95	0.80	0.91	0.89	0.81	
ADL + MTX Combination Therapy												
DAS28 <2.6	DAS28 <3.3	37	0.49	95	0.15	0.56	0.81	0.49	0.85	0.75	0.69	
CDAI REM	CDAI <7.0	29	0.41	103	0.02	0.86	0.86	0.41	0.98	0.86	0.86	
SDAI REM	SDAI <7.9	32	0.38	100	0.02	0.86	0.83	0.38	0.98	0.83	0.84	
DAS28 LDA	DAS28 <3.5	61	0.72	71	0.16	0.80	0.78	0.72	0.85	0.79	0.79	
CDAI LDA	CDAI <12.2	57	0.74	75	0.19	0.75	0.80	0.74	0.81	0.78	0.78	
SDAI LDA	SDAI <12.5	57	0.77	75	0.23	0.72	0.82	0.77	0.77	0.77	0.77	
ADL, adalimumab; MTX, methotrexate; DAS28, 28-joint disease activity score using C-reactive protein; CDAI, clinical disease activity index; SDAI, simplified disease activity index; REM, remission; PPV, positive/negative predictive value; AUC, area under the curve, n= number of patients with response												

ADL, adalimumab; MTX, methotrexate; DAS28, 28-joint disease activity score using C-reactive protein; CDAI, clinical disease activity index; SDAI, simplified disease activity index; REM, remission; P/NPV, positive/negative predictive value; AUC, area under the curve, n= number of patients with response

Conclusions: The ADL concentrations at Week 12 selected by the prediction model were weak predictors of disease control at 6 months, especially for pts on ADL+MTX combination therapy. However, using the model-selected cutoffs of composite clinical endpoints at Wk 12, disease control after 6 months of ADL ±MTX treatment could be correctly predicted in 70%–80% of pts.

REFERENCES:

- [1] Jani, et al. *Arthritis & Rheumatol* 2015.
- [2] Huang X, et al. *Statistics in Medicine* 2017.

Acknowledgements: AbbVie Inc was the study sponsor, contributed to study design, data collection, analysis and interpretation, and to writing, reviewing, and approval of final version. Medical writing support was provided by Naina Barretto, PhD, of AbbVie, Inc.

Disclosure of Interest: J. Smolen Grant/research support from: AbbVie Inc, Consultant for: AbbVie Inc, N. Mostafa Shareholder of: AbbVie Inc, Employee of: AbbVie Inc, X. Huang Shareholder of: AbbVie Inc, Employee of: AbbVie Inc, P. Noertersheuser Shareholder of: AbbVie Inc, Employee of: AbbVie Inc, B. Kluender Shareholder of: AbbVie Inc, Employee of: AbbVie Inc, K. Chen Shareholder of: AbbVie Inc, Employee of: AbbVie Inc, J. Kalabic Shareholder of: AbbVie Inc, Employee of: AbbVie Inc, I. Sainsbury Shareholder of: AbbVie Inc, Employee of: AbbVie Inc, R. Oerlemans Shareholder of: AbbVie Inc, Employee of: AbbVie Inc, S. Florentinus Shareholder of: AbbVie Inc, Employee of: AbbVie Inc, G. Burmester Grant/research support from: AbbVie Inc., Bristol-Myers Squibb, Merck, Roche, Pfizer, and UCB, Consultant for: AbbVie Inc., Bristol-Myers Squibb, Merck, Roche, Pfizer, and UCB, Speakers bureau: AbbVie Inc., Bristol-Myers Squibb, Merck, Roche, Pfizer, and UCB

DOI: 10.1136/annrheumdis-2018-eular.2721